Seven Fleet Capital Management
Seven Fleet Capital Management reported 85 stocks worth $512M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGON (26.1%), TNGX (10.9%) and RVMD (10.6%). Compared with Q2 2026, the fund opened new positions in DMRA, IMUX and UTHR, added to RVMD, ENTX and LQDA, trimmed TNGX, PHVS and ELVN and sold out of MIRM, MDGL and RLMD.
Latest filing: what Seven Fleet Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() CGON CG Oncology Inc | $134M | 26.1% | 1.9M | No change | 4 of 4 | |
| 2 | ![]() TNGX Tango Therapeutics Inc | $55.7M | 10.9% | 2.2M | −995K (−31%) | 4 of 4 | |
| 3 | ![]() RVMD Revolution Medicines Inc | $54.3M | 10.6% | 265K | +23K (+9%) | 4 of 4 | |
| 4 | ![]() PHVS Pharvaris N V | $22.2M | 4.3% | 700K | −74K (−10%) | 4 of 4 | |
| 5 | ![]() ENTX Entera Bio Ltd | $20M | 3.9% | 6.9M | +6.7M (+3486%) | 4 of 4 | |
| 6 | ![]() LQDA Liquidia Corporation | $18M | 3.5% | 596K | +340K (+132%) | 4 of 4 | |
| 7 | ![]() AVBP Arrivent Biopharma Inc | $13.7M | 2.7% | 451K | +205K (+83%) | 3 of 4 | |
| 8 | ![]() ELVN Enliven Therapeutics Inc | $12M | 2.4% | 262K | −103K (−28%) | 4 of 4 | |
| 9 | ![]() AVTX Avalo Therapeutics Inc | $11.8M | 2.3% | 773K | +1,895 (+0%) | 4 of 4 | |
| 10 | ![]() XNCR Xencor Inc | $11.1M | 2.2% | 445K | +77K (+21%) | 4 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() MIRM Mirum Pharmaceuticals Inc | $12.9M | 110K |
GALECTO INC | $7.4M | 284K |
![]() MDGL Madrigal Pharmaceuticals Inc | $2.7M | 4,973 |
![]() RLMD Relmada Therapeutics Inc | $2.4M | 348K |
![]() AGIO Agios Pharmaceuticals Inc | $2.1M | 57K |
🔒 Free account: see all 30.
Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Seven Fleet Capital Management 13F FAQ
What does Seven Fleet Capital Management own?
Seven Fleet Capital Management reported 85 stocks worth $512M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGON (26.1%), TNGX (10.9%) and RVMD (10.6%). The table above lists every position in the filing (the top 10 without an account).
What did Seven Fleet Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 20 new positions, 27 added to, 30 trimmed and 31 sold out. New positions include DMRA, IMUX and UTHR. It sold all of MIRM, MDGL and RLMD.
When will Seven Fleet Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Seven Fleet Capital Management's portfolio worth?
The Q3 2026 filing reports $512M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.






















